199 related articles for article (PubMed ID: 6265487)
21. New genetic insights in familial hyperaldosteronism.
Jackson RV; Lafferty A; Torpy DJ; Stratakis C
Ann N Y Acad Sci; 2002 Sep; 970():77-88. PubMed ID: 12381543
[TBL] [Abstract][Full Text] [Related]
22. Normokalemic hyperaldosteronism in patients with resistant hypertension.
Benchetrit S; Bernheim J; Podjarny E
Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
[TBL] [Abstract][Full Text] [Related]
23. Zona glomerulosa function after life-long suppression in two siblings with the hypertensive virilizing form of congenital adrenal hyperplasia.
Rodríguez Portales JA; Arteaga E; López Moreno JM; Biglieri EG
J Clin Endocrinol Metab; 1988 Feb; 66(2):349-54. PubMed ID: 3276723
[TBL] [Abstract][Full Text] [Related]
24. Primary aldosteronism: learning from the study of familial varieties.
Stowasser M; Gordon RD
J Hypertens; 2000 Sep; 18(9):1165-76. PubMed ID: 10994747
[TBL] [Abstract][Full Text] [Related]
25. A new family with dexamethasone-suppressible hyperaldosteronism: aldosterone unresponsiveness to angiotensin II.
Fallo F; Sonino N; Armanini D; Luzzi T; Pedini F; Pasini C; Mantero F
Clin Endocrinol (Oxf); 1985 Jun; 22(6):777-85. PubMed ID: 2990765
[TBL] [Abstract][Full Text] [Related]
26. Glucocorticoid-suppressible hyperaldosteronism. Ultrastructural observation of a case.
Matsuo K; Kawai K; Tsuchiyama H; Ueki Y
Acta Pathol Jpn; 1985 Nov; 35(6):1511-9. PubMed ID: 3004103
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of inhibition of aldosterone secretion by adrenocorticotropin.
Aguilera G; Fujita K; Catt KJ
Endocrinology; 1981 Feb; 108(2):522-8. PubMed ID: 6256154
[TBL] [Abstract][Full Text] [Related]
28. Dopaminergic regulation of aldosterone secretion: assessment in different subtypes of primary aldosteronism and in essential hypertension.
Veglio F; Pinna G; Rabbia F; Panarelli M; Bisbocci D; Melchio R; Chiandussi L
J Int Med Res; 1991; 19(1):44-9. PubMed ID: 1850365
[TBL] [Abstract][Full Text] [Related]
29. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance.
Stowasser M; Bachmann AW; Huggard PR; Rossetti TR; Gordon RD
J Clin Endocrinol Metab; 2000 Jun; 85(6):2160-6. PubMed ID: 10852446
[TBL] [Abstract][Full Text] [Related]
30. Effects of naloxone on adrenal cortex regulation in patients with primary aldosteronism.
Fallo F; Boscaro M; Sonino N; Mantero F
J Endocrinol Invest; 1988 Apr; 11(4):261-5. PubMed ID: 2970500
[TBL] [Abstract][Full Text] [Related]
31. Effects of naloxone on the pituitary-adrenal axis in patients with dexamethasone-suppressible hyperaldosteronism.
Fallo F; Boscaro M; Sonino N; Mantero F
Clin Endocrinol (Oxf); 1987 Feb; 26(2):163-8. PubMed ID: 2822294
[TBL] [Abstract][Full Text] [Related]
32. Circadian rhythm of plasma aldosterone concentration in patients with primary aldosteronism.
Kem DC; Weinberger MH; Gomez-Sanchez C; Kramer NJ; Lerman R; Furuyama S; Nugent CA
J Clin Invest; 1973 Sep; 52(9):2272-7. PubMed ID: 4353776
[TBL] [Abstract][Full Text] [Related]
33. Primary aldosteronism: hypertension with a genetic basis.
Gordon RD; Klemm SA; Tunny TJ; Stowasser M
Lancet; 1992 Jul; 340(8812):159-61. PubMed ID: 1352575
[TBL] [Abstract][Full Text] [Related]
34. Dexamethasone suppressible hyperaldosteronism in a child with nephrosclerosis.
Lee SM; Lightner E; Witte M; Oberfield S; Levine L; New MI
Acta Endocrinol (Copenh); 1982 Feb; 99(2):251-5. PubMed ID: 6277130
[TBL] [Abstract][Full Text] [Related]
35. Dexamethasone-suppressible hyperaldosteronism: a large new kindred.
O'Mahony S; Burns A; Murnaghan DJ
J Hum Hypertens; 1989 Aug; 3(4):255-8. PubMed ID: 2552113
[TBL] [Abstract][Full Text] [Related]
36. Aldosterone response to adrenocorticotrophin and furosemide in primary aldosteronism after prolonged spironolactone treatment.
Yagi A; Ichikawa S; Sakamaki T; Ono Z; Sato K; Nakamura T; Sakamoto H; Murata K
Eur J Endocrinol; 1994 Sep; 131(3):215-20. PubMed ID: 7921203
[TBL] [Abstract][Full Text] [Related]
37. Adrenal transitional zone steroids, 18-oxo and 18-hydroxycortisol, useful in the diagnosis of primary aldosteronism, are ACTH-dependent.
Hamlet SM; Gordon RD; Gomez-Sanchez CE; Tunny TJ; Klemm SA
Clin Exp Pharmacol Physiol; 1988 Apr; 15(4):317-22. PubMed ID: 2856057
[TBL] [Abstract][Full Text] [Related]
38. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism.
Geller DS; Zhang J; Wisgerhof MV; Shackleton C; Kashgarian M; Lifton RP
J Clin Endocrinol Metab; 2008 Aug; 93(8):3117-23. PubMed ID: 18505761
[TBL] [Abstract][Full Text] [Related]
39. Are there unknown mineralocorticoids in low-renin essential hypertension?
Hollifield JW; Slaton PE; Wilson HM; Sennett JA; Yarbro L; Island DP; Liddle GW
Mayo Clin Proc; 1977 May; 52(5):329-33. PubMed ID: 323587
[TBL] [Abstract][Full Text] [Related]
40. Control of plasma aldosterone in primary aldosteronism: distinction between adenoma and hyperplasia.
Ganguly A; Melada GA; Luetscher JA; Dowdy AJ
J Clin Endocrinol Metab; 1973 Nov; 37(5):765-75. PubMed ID: 4356136
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
